Different perspectives on pricing and value of cancer medicines, including specific challenges related to combination therapies

A key issue for patient advocates is to understand the two perspectives, from the patient community and from an industry/economics perspective, on pricing and pricing models including aspects of the difference between what is “cost effective”, what is methodologically sound, what is “ethical”.

Presentation at the WECAN Academy 2019:

Different perspectives on pricing and value of cancer medicines, including specific challenges related to combination therapies

Presenter: Stefan Weber, AMGEN & Zack Pemberton-Whitely, Acute Leukaemia Network

The following presentation held at the WECAN Academy 2019 will help you to understand:

  • Different perspectives on what constitutes a “fair price”
  • Different pricing models for therapies that are currently being discussed or used (value-based pricing, cost-plus, price referencing, differential pricing, return on R&D costs / investment, …), and their fundamental pros and challenges from an advocacy perspective
  • Talking about value: what is “value”, what is measured and what not and how is this relevant from an advocacy perspective? Should a different value be assigned to potentially curative and/or end of life therapies – and why / why not?
  • Dilemma in pricing: international reference pricing and the pros & cons of transparency – does advocating as patients for more transparency also bring new risks on access?
  • The specific challenges of combination pricing when multiple drugs are combined: what does: “not even cost effective even at zero price” mean and what should advocates do about it?

 

Last updated byJan
278 reads
Was this article of help to you?0010

Leave A Comment